- $2.10bn
- $1.94bn
- $276.26m
Vericel Corp reports results for the quarter ended in March - Earnings Summary
Brief: Vericel Reports Q1 Loss Per Share $0.07
Vericel Corp expected to post a loss of 4 cents a share - Earnings Preview
Brief: Vericel Set To Join S&P SmallCap 600
Brief: Vericel Reports Fourth Quarter And Full-Year 2020 Financial Results, Provides Full-Year 2021 Financial Guidance
Brief: Vericel Announces Termination Of Shareholder Rights Agreement
Brief: Vericel Announces Appointment Of Joe Mara As Chief Financial Officer
Brief: Vericel Corp - Preliminary Total Net Revenues For Q4 2020 Are Expected To Be In Range Of $44.9-$45.4 Mln
Brief: Vericel Announces Expansion Of Maci Coverage By Unitedhealthcare To Include Patella And Multiple Cartilage Defects In The Knee
Brief: Vericel Reports Q3 Earnings Per Share $0.08
U.S. STOCKS ON THE MOVE-Twitter, Caterpillar, Wells Fargo, Restaurant Brands
U.S. STOCKS ON THE MOVE-Abercrombie & Fitch, Boeing, Wells Fargo, Goldman Sachs
Vericel Corp: Preliminary Q3 revenue up 5%, shares rise
MedTech: Strong Q3 recovery not enough to impress investors - BTIG
U.S. RESEARCH ROUNDUP- ACI Worldwide, CVS Health, Zoominfo Technologies
Brief: Vericel Announces FDA Acceptance Of Biologics License Application For NexoBrid
Brief: Vericel Corp Says CFO Gerard Michel Intends To Resign
Brief: Mediwound, Vericel Announce Acceptance Of The First Delivery Of Nexobrid To Barda For Emergency Response Preparedness
Brief: Mediwound, Vericel Announce Acceptance Of First Delivery Of Nexobrid To BARDA